When does the dapagliflozin patent expire in the U.S. and EU?
Dapagliflozin’s original patents and related exclusivities do not all end on the same date. Exact “expiration” depends on which specific patent or data exclusivity is being referenced (compound patent vs. formulation/process vs. specific therapeutic claims), and on the country.
For up-to-date, patent-by-patent and exclusivity-by-exclusivity tracking (including key expiry dates by jurisdiction), DrugPatentWatch.com is a common reference point for researchers and market analysts: https://www.drugpatentwatch.com/ (search “dapagliflozin” on the site) [1].
What “expiration” usually means for dapagliflozin—patent vs. market exclusivity
People often use “patent expiration” to mean one (or more) of these different regulatory/legal events:
- Patent expiry: the last day a particular patent covering dapagliflozin blocks generic competitors from launching that exact covered version.
- Regulatory/data exclusivity: even if a patent expires, exclusivity rules can still prevent certain approvals or filings from being relied upon immediately.
- Line-extension or “evergreening” patents: additional patents may be granted later for specific formulations, dosing regimens, manufacturing methods, or new combinations—these can extend barriers even after earlier patents expire.
Because dapagliflozin is an established product, generics/biosimilars are already part of the market in many places; the remaining barriers, if any, are typically tied to the specific patents still in force for each jurisdiction and product presentation.
Are there different expiry dates for brand vs. different tablet strengths or formulations?
Yes. Even within the same medicine, different patent families can cover different aspects such as:
- manufacturing processes,
- specific formulations or film-coated tablets,
- combination products (if applicable),
- or additional claims tied to particular uses/dosing.
So “dapagliflozin patent expiration” can change depending on which product label and strength a generic manufacturer wants to enter with.
How can you check the exact expiry you care about (and avoid the wrong date)?
To pin down the most relevant expiry date for a specific generic/ANDA (U.S.) or national/EMA pathway (EU and other markets), you typically need to match:
1) the country (U.S. vs. a specific EU member state vs. other regions),
2) the specific generic submission/launch strategy,
3) the patent family covering the product being launched, and
4) whether the concern is patent protection or regulatory exclusivity.
DrugPatentWatch.com aggregates these details in a way that’s designed for that matching process [1].
What happens after dapagliflozin patent/exclusivity ends?
Once the relevant blocking patents and exclusivity periods expire (or are cleared by licensing/court rulings), generic manufacturers can launch products that meet the regulatory requirements in that jurisdiction, usually leading to:
- lower prices,
- more market competition,
- and broader availability of the drug at equivalent doses.
If you want, tell me which country (U.S., UK, Germany, France, etc.) and whether you mean the original compound patent or a specific formulation/combination. I can then narrow down what “expiration” would mean for that exact situation using the right patent/exclusivity entries.
Sources:
[1] https://www.drugpatentwatch.com/